Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Comment by walkingredon Mar 15, 2016 8:19pm
307 Views
Post# 24662667

RE:ProMetic announces the addition of scleroderma to PBI-4050's

RE:ProMetic announces the addition of scleroderma to PBI-4050'sI agree with F21.  

We know it works on fibrosis all kinds, we know it's tolerable. With the new money that came in, perhaps a new deal that's coming in (wishful/immenent?).. they got money to push.

Kind of like the diabetic wound thing. Bonus shot on goal. Tons of RND finding similar untreatable anything fibrosis. Maybe the Thompson gang released the hounds. Maybe patients had the skin scleroderma as an after effect of one of the fibrosis illnesses we're treating, and they just found it. Who knows.

More attention to our product and what we can do with a single protein, of the ANY we want to target and pluck.  High yield high purity high efficiency Prometic styles.


Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse